General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Inqovi (decitabine-cedazuridine)
Status:
Concluded with an LOI
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients
Last updated August 25, 2022
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma in adult patients (in combination with fluoropyrimidine- and platinum-containing chemotherapy)
Last updated August 25, 2022
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Esophageal or gastroesophageal junction cancer, completely resected, adjuvant treatment in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT)
Last updated August 25, 2022
Entresto (sacubitril/valsartan)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Heart failure, NYHA class II or III
Last updated August 17, 2022
Entresto (sacubitril/valsartan)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Heart failure, NYHA class II or III
Last updated August 17, 2022
Waymade-Trientine (trientine hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Waymade Canada Inc
Indication:
Wilson's Disease
Last updated August 11, 2022
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Psoriatic Arthritis
Last updated August 8, 2022
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Rheumatoid Arthritis
Last updated August 8, 2022
pdp-levETIRAcetam (levetiracetam)
Status:
Concluded with an LOI
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Epilepsy
Last updated August 5, 2022
Status:
Negotiations were not pursued
Manufacturer:
Incyte Biosciences Canada Corporation
Indication:
Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) in adults with previously treated CCA with a FGFR2 fusion or other rearrangement
Last updated July 29, 2022